ALLMedicine™ Platelet Aggregation Center

Jun 26th, 2022 - The aim of this study was to investigate the diagnostic accuracy of the flag PLT-Clumps from the WNR/WDF and the PLT-F channels from Sysmex XN and to study how different cut-offs for investigation for pseudothrombocytopenia (PTCP) and the definiti...

Jun 24th, 2022 - Study Description: This study will serve to provide tissue samples from individuals with healthy vasculature for mechanistic studies of vascular inflammation and thrombosis. Objectives: Primary Objective: To collect samples from healthy volunteers...

Jun 24th, 2022 - Acute lung injury, referred to as the acute chest syndrome, is a major cause of morbidity and mortality in patients with sickle cell disease (SCD), which often occurs in the setting of a vaso-occlusive painful crisis. P-selectin antibody therapy r...

Jun 19th, 2022 - To observe the combination effects of Panax notoginseng saponins (PNS)and dual antiplatelet drugs (DAPT), and to explore the mechanism via cyclooxygenase /prostaglandin pathway. Right carotid artery thrombosis was induced in Wistar rats by infiltr...

Jun 17th, 2022 - Secretory granules are key elements for platelet functions. Their biogenesis and integrity are regulated by fine-tuned mechanisms that need to be fully characterized. Here, we investigated the role of the phosphoinositide 5-kinase PIKfyve and its ...

Oct 14th, 2014 - Patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) like polycythemia vera and essential thrombocythemia are at increased risk of arterial and venous thrombosis. Strategies of prevention may consist of platelet aggreg...

Jun 24th, 2022 - Study Description: This study will serve to provide tissue samples from individuals with healthy vasculature for mechanistic studies of vascular inflammation and thrombosis. Objectives: Primary Objective: To collect samples from healthy volunteers...

Jun 14th, 2022 - Ticagrelor is a commercially available antiplatelet adenosine diphosphate (ADP) antagonists. They exert their antiplatelet effects by binding to P2Y12 receptors on the platelet surface. Ticagrelor is used in combination with aspirin to prevent and...

Jun 14th, 2022 - The trial was a double-blind randomized dietary intervention study with a 1:1 allocation ratio, conducted in accordance with the Declaration of Helsinki. This study compared two treatments, i.e., farmed fish fed with olive pomace enriched diet (en...

Jun 13th, 2022 - Purpose: In this aim, the investigators will test the hypothesis that n-3 PUFAs modify aspirin anti-platelet response, by measuring and comparing three different indicators of aspirin response in individuals with extremely high and low RBC n-3 PUF...

Jun 10th, 2022 - In the past we used 30% lower dose of abciximab compared to the cardiac trials and the discontinued ABESTT stroke trial. There were no symptomatic intracranial hemorrhages or thromboyctopenia in our study. Based on the safety and efficacy results ...

May 18th, 2022 - (Reuters) - The U.S. Food and Drug Administration has decided not to authorize the antidepressant fluvoxamine to treat COVID-19, saying that the data has not shown the drug to be an effective therapeutic for fighting the virus. "Based on the revie...

Feb 23rd, 2022 - Craig Kessler, MD: Sutimlimab is a humanized monoclonal antibody that selectively inhibits activation of the complement pathway by binding to complement 1S. This drug, which is not approved, will be marketed by Sanofi. It was originally developed ...

Nov 17th, 2021 - The experimental monoclonal antibody bentracimab, which reverses the antiplatelet effects of ticagrelor, appears to be heading toward regulatory approval, on the basis of an interim analysis of the phase 3 REVERSE-IT trial. Dr.

Aug 16th, 2021 - Patients undergoing percutaneous coronary intervention (PCI) after recent marijuana smoking tended to have different complications than non-users, researchers found. Marijuana users -- representing a modest 3.5% of PCI recipients in the Blue Cross...

Jun 30th, 2021 - A phase 3 study testing the safety and efficacy of the fast-acting, self-administered P2Y12 receptor antagonist selatogrel (Idorsia Pharmaceuticals) for the treatment of suspected acute myocardial infarction (AMI) is underway, the company has anno...